Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
No positive correlation between 3-HK and TNF-α was seen in PD.
|
31654722 |
2020 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since depression is a common co-morbid condition with PD, we undertook this study to determine whether Hc-TeTx might also show antidepressant-like properties and whether central brain-derived neurotrophic factor (BDNF) and/or tumor necrosis factor (TNF)-alpha are also affected by it.
|
31125623 |
2019 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased GLRX copy number in PD patients was associated with earlier PD onset; and Grx1 levels correlated with levels of proinflammatory tumor necrosis factor-α in mouse and human brain samples.
|
29183158 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, FMD decreased the number of glial cells as well as the release of TNF-α and IL-1β in PD mice, showing that FMD also inhibited neuro-inflammation.
|
30815845 |
2019 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Human neuroblastoma cell line SH-SY5Y was treated with 1-Methyl-4-phenylpyridinium (MPP<sup>+</sup>) to mimic PD model in vitro. qRT-PCR was employed to detect the expression of NEAT1, IL-1β, IL-6 and TNF-α.
|
31228597 |
2019 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Pretreatment with CUMS for 14 days increased the levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-a) in the serum, and increased the expression of NLRP-3, ASC, Casepase-1 in the substantia nigra of PD rats.
|
30658122 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute to classical neuronal mechanisms underpinning the pathophysiology of l-dopa-induced dyskinesia, a motor complication associated with l-dopa therapy in Parkinson's disease.
|
31335998 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, TNFα-mediated neurotoxicity appears to occur in early PD.
|
30954070 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In pair-wise FDR-corrected non-parametric comparisons 12 cytokines (FGF-2, eotaxin, fractalkine, IFN-α2, IL-10, MCP-3, IL-12p40, MDC, IL-17, IL-7, MIP-1β, TNF-α) were significantly higher in MSA vs. non-MSA cases (PD + controls pooled together).
|
31178335 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to characterize the activation of Schwann cells (SCs) and the increase of expression of inflammatory cytokines IL-1β, IL-6, and TNF-α in the sural nerve of PD, and further explore whether peripheral nerve inflammation is the cause of PD sensory disturbances.
|
31828965 |
2019 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of TNF-α is associated with numerous neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease.
|
31443122 |
2019 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma concentrations of IL-1β, IL-2, IL-4, IL-6, IL-13, IL-18, GM-CSF, IFNγ, and TNFα were measured by a multiplex immunoassay and relationships between microbiota, clinical characteristics, and cytokine levels were analyzed in the PD group.
|
31248424 |
2019 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After the 12-week intervention, compared with the placebo, omega-3 fatty acids and vitamin E co-supplementation downregulated gene expression of tumor necrosis factor alpha (TNF-α) (P = 0.002) in PBMC of subjects with PD.
|
30554092 |
2019 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There are conflicting studies to serum level of TNF-α in PD.
|
29408778 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α, which is highly toxic to dopaminergic neurons, is implicated as a major mediator of neuroinflammation in PD.
|
30515090 |
2018 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increased inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1 β), and tumor necrosis factor-α (TNF-α) are associated with Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
|
28856541 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that the specificity of extrapyramidal to NS raises the intriguing question of whether specific inflammatory pathways involving TNF-α play a role in the pathogenesis of PD and therefore may be a therapeutic target.
|
29054587 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In CSF and serum, inflammatory factors behaved differently, with increased CSF TNFα indicating rapid PD progression, and increased IL-1β in serum.
|
29478949 |
2018 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To study the association between Parkinson's disease (PD)-related pain and plasma interleukin (IL)‑1, IL‑6, IL‑10, and tumour necrosis factor (TNF)‑α levels.
|
30063943 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accordingly, IL-1β and TNF-α might be considered therapeutically to ameliorate skeletal muscle abnormalities characterizing PD.
|
30400118 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
After the 12-week intervention, compared with the placebo, probiotic intake downregulated gene expression of interleukin-1 (IL-1) (P = 0.03), IL-8 (P < 0.001) and tumor necrosis factor alpha (TNF-α) (P=0.04) in PBMC of subjects with PD.
|
30041526 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
To detect the expression of high-mobility group box protein 1 (HMGB1) and toll-like receptor 4 (TLR4) and their downstream signaling factors-myeloid differentiation factor 88 (MyD88), nuclear factor kappa B (NF-κB), and tumor necrosis factor alpha (TNF-α)-in the sera of patients with Parkinson's disease (PD) in order to evaluate the relationship of the HMGB1-TLR4 axis with PD development and progression.
|
29670828 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the pro-inflammatory tumor necrosis factor (TNF) is known to be toxic to catecholaminergic cells (see Parkinson disease), and this may prevent anti-inflammatory effects in inflamed tissue.
|
29941879 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
|
29710331 |
2018 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
On a sensitive electrochemiluminescence-based platform (Quickplex, Meso Scale Discovery®), we examined a panel of C-reactive protein (CRP) and eight selected cytokines, IFN-γ, IL-10, IL-18, IL-1β, IL-4, IL-6, TGF-β1, and TNF-α, among patients with PD (n = 46), MSA (n = 35), and PSP (n = 39) or controls (n = 31).
|
30390673 |
2018 |